A NOVEL NON-INVASIVE LIQUID BIOPSY TEST FOR MONITORING OF AGGRESSIVE LYMPHOMA
​
LymFollow is an innovative commercial diagnostic kit tailored for the monitoring and analysis of aggressive Lymphoma and its response to therapy.
​
This advanced solution utilizes a single blood biomarker for comprehensive testing.
LYMPHOMA CURRENT STANDARD OF CARE
Although lymphoma ranks as the 5th most prevalent blood cancer, the absence of biomarkers for evaluating drug response and detecting disease recurrence prior to clinical symptoms has been a prevailing issue. This is particularly significant given that a subset of patients won't achieve complete remission after initial treatment, with approximately 30% facing the risk of relapse.
Presently, PET/CT imaging os the gold standard for diagnostics, evaluating therapy response and follow-up.
Nonetheless, clinical recommendations advise against frequent PET/CT scans due to radiation exposure concerns and limited efficacy in predicting disease relapses.
NOVEL PROMISE THROUGH INNOVATIVE TECHNOLOGY
The innovative LymFollow kit leverages the discovery of elevated Fibrinogen-like protein (FGL2) activity in peripheral blood cells of patients with malignancies.
In clinical settings, this predictive biomarker has showcased its efficacy as a non-invasive effective therapy response and relapse monitor among Non-Hodgkin Lymphoma (NHL) patients.
​
LymFollow empowers healthcare professionals with invaluable insights into disease progression, thereby optimizing treatment approaches and lowering treatment cost.
